Principal Financial Group Inc. Acquires 3,668 Shares of LivaNova PLC (NASDAQ:LIVN)

Principal Financial Group Inc. raised its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 2.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 179,546 shares of the company’s stock after purchasing an additional 3,668 shares during the quarter. Principal Financial Group Inc.’s holdings in LivaNova were worth $7,053,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. PNC Financial Services Group Inc. lifted its position in LivaNova by 29.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company’s stock valued at $292,000 after purchasing an additional 1,424 shares during the last quarter. GAMMA Investing LLC lifted its position in LivaNova by 2,299.7% during the first quarter. GAMMA Investing LLC now owns 8,759 shares of the company’s stock valued at $344,000 after purchasing an additional 8,394 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new position in LivaNova during the fourth quarter valued at $2,772,000. Envestnet Asset Management Inc. lifted its position in LivaNova by 15.4% during the fourth quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company’s stock valued at $2,034,000 after purchasing an additional 5,850 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC lifted its position in LivaNova by 147.2% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 98,940 shares of the company’s stock valued at $4,582,000 after purchasing an additional 58,911 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Wall Street Zen lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 8th. Wolfe Research upgraded shares of LivaNova from a “peer perform” rating to an “outperform” rating and set a $60.00 target price for the company in a report on Tuesday, May 20th. Needham & Company LLC restated a “buy” rating and issued a $64.00 target price on shares of LivaNova in a report on Tuesday, May 13th. Robert W. Baird raised their target price on shares of LivaNova from $55.00 to $61.00 and gave the stock an “outperform” rating in a report on Thursday, May 8th. Finally, Barclays lowered their target price on shares of LivaNova from $56.00 to $55.00 and set an “equal weight” rating for the company in a report on Thursday, May 8th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $59.29.

LivaNova Trading Down 1.2%

LIVN stock opened at $43.43 on Wednesday. The company has a market capitalization of $2.37 billion, a PE ratio of -10.62 and a beta of 0.90. LivaNova PLC has a 12 month low of $32.48 and a 12 month high of $57.35. The firm’s 50-day moving average is $44.85 and its 200 day moving average is $43.23. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.58 and a quick ratio of 1.37.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.